Self-copying RNA vaccine wins first full approval: what’s next?

Elie Dolgin • December 6, 2023

Researchers look ahead to the potential uses and benefits of a technology that has been more than 20 years in the making.

The approval of yet another RNA-based vaccine for COVID-19 might not seem momentous. But the endorsement last week by Japanese authorities of a jab against SARS-CoV-2 constructed using a form of RNA that can make copies of itself inside cells — the first ‘self-amplifying’ RNA (saRNA) granted full regulatory approval anywhere in the world — marks a pivotal advance.


The new vaccine platform could provide potent defence against various infectious diseases and cancers. And because it could be used at a lower dose, it might have fewer side effects than other messenger RNA (mRNA) treatments have.


Continue reading at Nature.

Girl jumping with arms bandaged
By Elie Dolgin August 27, 2025
Fresh treatments shift the focus from symptom management to repair.
By Elie Dolgin August 27, 2025
Smart algorithms take aim at antimicrobial resistance.